Document:

Employment Agreement (William Lambert)

 Exhibit 10.24 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 This Executive Employment Agreement
(the “Agreement”), is entered into as of October 27, 2010 (the “Effective Date”), by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and William Lambert (the
“Executive”). 
 RECITALS 

WHEREAS, the Company wishes to continue to employ the Executive, and the Executive desires to continue to be employed by the
Company, for such purpose and upon the terms and conditions hereinafter provided; and 
 WHEREAS, the parties wish to
establish the terms of the Executive’s future employment with the Company and set out fully their respective rights, obligations and duties. 
 AGREEMENT 
 In consideration of the promises and the terms and
conditions set forth in this Agreement, the parties agree as follows: 
 1. Title and Capacity. The Company hereby agrees
to continue to employ the Executive, and the Executive hereby accepts continued employment with the Company, under the terms set forth in this Agreement. The Executive will serve as the Senior Vice President of Pharmaceutical Development of the
Company and shall perform such duties as are ordinary, customary and necessary in such role. The Executive will report directly to the Chief Executive Officer of the Company. The Executive shall devote his full business time, skill and attention to
the performance of his duties on behalf of the Company. 
 2. Compensation and Benefits. 

(a) Salary. The Company agrees to pay the Executive an annual base salary of Two Hundred and Twenty Thousand
Dollars ($220,000) payable in accordance with Company’s customary payroll practice (the “Base Salary”). The Executive’s Base Salary shall be reviewed periodically by the Board of Directors of the Company (the
“Board”); provided, however, that any such review will not necessarily result in an adjustment to the Executive’s Base Salary. Any change in the Executive’s Base Salary must be approved by the Board.

 (b) Bonus. The Executive is eligible to receive, in addition to the Base Salary and subject to the
terms hereof and at the full discretion of the Board, a targeted incentive bonus of thirty percent (30%) of Base Salary (the “Targeted Incentive Bonus”). The Targeted Incentive Bonus shall be based on the Executive’s and
the Company’s performance during the applicable fiscal year, as determined by the Board. The Targeted Incentive Bonus criteria or “goals” will be determined by agreement between the Board and the Executive at beginning of each fiscal
year. The award of the Target Incentive Bonus may be in an amount either above or below the amount specified by the Board at the beginning of each fiscal year based on the ultimate performance assessed by the Board. 

  

 The Targeted Incentive Bonus, if awarded, shall be payable in the first
payroll period in 2012, but in no event later than March 15, 2012. Targeted Incentive Bonuses for subsequent years shall be determined and approved by the Board in its sole discretion. 

All salary and bonuses shall be subject to all applicable withholdings and deductions. 

(c) Stock Options. On September 2, 2010, the Company granted to the Executive two stock options (each an
“Option” and collectively, the “Options”) to purchase an aggregate of five hundred and fifty thousand (550,000) shares of the Company’s common stock, $0.001 par value per share (the “Option
Shares”), pursuant to the Company’s 2007 Stock Option/Stock Issuance (the “Plan”). The exercise price, vesting schedule and other terms for each of the Options are set forth in the notice of grant and option agreement
for each such Option and the Options are subject to accelerated vesting as set forth in Section 3 hereof. Additional equity incentives, if any, shall be determined by the Board (or a committee thereof) in its sole discretion. All share figures
set forth herein shall be subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations and similar events. 
 (d) Benefits. The Executive (and, where applicable, the Executive’s qualified dependents) will be eligible to participate in health insurance and other employee benefit plans and policies
established by the Company for its executive team from time to time on substantially the same terms as are made available to other such employees of the Company generally. The Executive’s participation (and the participation of the
Executive’s qualified dependents) in the Company’s benefit plans and policies will be subject to the terms of the applicable plan documents and the Company’s generally applied policies, and the Company in its sole discretion may from
time to time adopt, modify, interpret or discontinue such plans or policies. 
 (e) Expenses. The Company
will reimburse the Executive for all reasonable and necessary expenses incurred by the Executive in connection with the Company’s business, in accordance with the applicable Company policy as may be amended from time to time. 

(f) Vacation and Holidays. The Executive shall be eligible for thirty (30 days’ paid vacation/flexible time
off per calendar year subject to the applicable terms and conditions of the Company’s vacation policy and applicable law. 
 (g) Termination of Benefits. Except as set forth in Section 3 or as otherwise specified herein or in any other agreement between the Executive and the Company, if the Executive’s
employment is terminated by the Company for any reason, with or without Cause (as defined below), or if the Executive resigns the Executive’s employment voluntarily, with or without Good Reason (as defined below), no compensation or other
payments will be paid or provided to the Executive for periods following the date when such a termination of employment is effective, provided that any rights the Executive may have under the Company’s benefit plans shall be determined under
the provisions of such plans. If the Executive’s employment terminates as a result of the Executive’s death or disability, no compensation or payments will be made to the Executive other than those to which the Executive may otherwise be
entitled under the benefit plans of the Company. 

  
 2 

 3. Compensation and Benefits Upon Termination of Employment. Upon termination of the
Executive’s employment (such date of termination being referred to as the “Termination Date”), the Company will pay the Executive the compensation and benefits as described in this Section 3. 

(a) General Benefits Upon Termination. The Company will pay the Executive on or about the Termination Date all
salary and vacation/personal time off pay, if any, that has been earned or accrued through the Termination Date and that has not been previously paid. 

(b) Termination without “Cause” or for “Good Reason”. In the event that the
Company terminates the Executive’s employment without Cause (as defined below) or, in the event the Executive terminates his employment for Good Reason (as defined below), in each case, (i) the Executive shall be entitled to receive
(A) continuing payments of the then effective Base Salary for a period of nine (9) months beginning on the Payment Commencement Date and payable in accordance with the Company’s payroll policies and (B) the benefits set forth in
Section 3(e), and (ii) the Executive shall be entitled to acceleration of vesting of such number of Option Shares as would have vested in the nine (9) month period following the Termination Date had the Executive continued to be
employed by the Company for such period, provided, however that in each case the receipt of such payments and benefits is expressly contingent upon the Executive’s execution and delivery of a severance and release of claims
agreement drafted by and satisfactory to counsel for the Company (the “Release”) which Release must be executed and become effective within sixty (60) days following the Termination Date. The payments and benefits shall be paid
or commence on the first payroll period following the date the Release becomes effective (the “Payment Commencement Date”). Notwithstanding the foregoing, if the 60th day following the Termination Date occurs in the calendar year following the termination, then the Payment
Commencement Date shall be no earlier than January 1st of such subsequent calendar year. The provision of payments and benefits pursuant to this Section shall be subject to the terms and conditions set forth on Exhibit A. 

(c) Termination without “Cause” or for “Good Reason” Prior to or Following a Change of Control.
In the event that the Company terminates the Executive’s employment without Cause (as defined below) or, in the event the Executive terminates his employment for Good Reason (as defined below), in each case, within thirty (30) days prior
to, or twelve (12) months following, the consummation of a Change of Control, then (i) the Executive shall be entitled to receive (A) continuing payments of the then effective Base Salary for a period of nine (9) months beginning on
the Payment Commencement Date and payable in accordance with the Company’s payroll policies and (B) the benefits set forth in Section 3(e), and (ii) acceleration of vesting of one hundred percent (100%) of the then
unvested Option Shares, provided, however that in each case: (x), the receipt of such payments and benefits is expressly contingent upon the Executive’s execution and delivery of a Release as described above drafted by and satisfactory to
counsel for the Company, which Release must be executed and become effective within sixty (60) days following the Termination Date. The provision of payments and benefits pursuant to this Section shall be subject to the terms and conditions set
forth in Exhibit A. 

  
 3 

 (d) Definitions. 

(i) “Change of Control” means (A) a merger or consolidation of either the Company or Pacira, Inc., a
Delaware corporation (“Parent”) into another entity in which the stockholders of the Company or Parent (as applicable) do not control fifty percent (50%) or more of the total voting power of the surviving entity (other than a
reincorporation merger); (B) the sale, transfer or other disposition of all or substantially all of the Company’s assets in liquidation or dissolution of the Company; or (C) the sale or transfer of more than fifty percent
(50%) of the outstanding voting stock of the Company. In the case of each of the foregoing clauses (A), (B) and (C), a Change of Control as a result of a financing transaction of the Company or Parent shall not constitute a Change of
Control for purposes of this Agreement 
 (ii) “Cause” means (A) the Executive’s
failure to substantially perform his duties to the Company after there has been delivered to the Executive written notice setting forth in detail the specific respects in which the Board believes that the Executive has not substantially performed
his duties and, if the Company reasonably considers the situation to be correctable, a demand for substantial performance and opportunity to cure, giving the Executive thirty (30) calendar days after he receives such notice to correct the
situation; (B) the Executive’s having engaged in fraud, misconduct, dishonesty, gross negligence or having otherwise acted in a manner injurious to the Company or in intentional disregard for the Company’s best interests; (C) the
Executive’s failure to follow reasonable and lawful instructions from the Board and the Executive’s failure to cure such failure after receiving twenty (20) days advance written notice; (D) the Executive’s material breach of
the terms of this Agreement or the Employee Proprietary Information and Inventions Assignment Agreement or any other similar agreement that may be in effect from time to time; or (E) the Executive’s conviction of, or pleading guilty or
nolo contendere to, any misdemeanor involving dishonesty or moral turpitude or related to the Company’s business, or any felony. 
 (iii) “Good Reason” means the occurrence of any one or more of the following events without the prior written consent of the Executive: (A) any material reduction of the then
effective Base Salary other than in accordance with this Agreement or which reduction is not related to a cross-executive team salary reduction; (B) any material breach by the Company of this Agreement; or (C) a material reduction in the
Executive’s responsibilities or duties, provided that in the case of clause (C), a mere reassignment following a Change of Control to a position that is substantially similar to the position held prior to the Change of Control transaction shall
not constitute a material reduction in job responsibilities or duties; provided, however, that no such event or condition shall constitute Good Reason unless (x) the Executive gives the Company a written notice of termination for
Good Reason not more than ninety (90) days after the initial existence of the condition, (y) the grounds for termination (if susceptible to correction) are not corrected by the Company within thirty (30) days of its receipt of such
notice and (z) the Termination Date occurs within one (1) year following the Company’s receipt of such notice. 
 (e) Benefits Continuation. If the Executive’s employment is terminated pursuant to Section 3(b) or Section 3(c) and provided that the Executive is eligible for and
elects to continue receiving group health and dental insurance pursuant to the federal “COBRA” law, 29 U.S.C. § 1161 et seq., the Company will, for a twelve (12) month period following the Payment Commencement
Date (the “Benefits Continuation Period”), continue to pay the share of 

  
 4 

 
the premium for such coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage. The remaining balance of any premium costs shall
be paid by the Executive on a monthly basis for as long as, and to the extent that, the Executive remains eligible for COBRA continuation. Notwithstanding the above, in the event the Executive becomes eligible for health insurance benefits from
a new employer during the Benefits Continuation Period, the Company’s obligations under this Section 3(e) shall immediately cease and the Executive shall not be entitled to any additional monthly premium payments for health
insurance coverage. Similarly, in the event the Executive becomes eligible for dental insurance benefits from a new employer during the Benefits Continuation Period, the Company’s obligations under this Section 3(e) shall
immediately cease and the Executive shall not be entitled to any additional monthly premium payments for dental insurance. The Executive hereby represents that he will notify the Company in writing within three (3) days of becoming
eligible for health or dental insurance benefits from a new employer during the Benefits Continuation Period 

(f) Death. This Agreement shall automatically terminate upon the death of the Executive and all monetary
obligations of Company under Section 2 of this Agreement shall be pro rated to the date of death and paid to the Executive’s estate. 
 (g) Disability. The Company may terminate the Executive’s employment if the Executive is unable to perform any of the duties required under this Agreement for a period of three
(3) consecutive months due to a “Total and Permanent Disability”. The term “Total and Permanent Disability” shall mean the existence of a permanent physical or mental illness or injury, which renders the Executive
incapable of performing any material obligations or terms of this Agreement. Any dispute regarding the existence of a Total and Permanent Disability shall be resolved by a panel of three (3) physicians, one selected by Company, one selected by
the Executive, and the third selected by the other two physicians. A termination of employment pursuant to this Section 3(f) shall constitute a termination for Cause. 
 4. At-Will Employment. The Executive will be an “at-will” employee of the Company, which means the employment relationship can be terminated by either the Executive or the Company for any
reason, at any time, with or without prior notice and with or without cause. The Company makes no promise that the Executive’s employment will continue for any particular period of time, nor is there any promise that it will be terminated only
under particular circumstances. No raise or bonus, if any, shall alter the Executive’s status as an “at-will” employee or create any implied contract of employment. Discussion of possible or potential benefits in future years is not
an express or implied promise of continued employment. No manager, supervisor or officer of the Company has the authority to change the Executive’s status as an “at-will” employee. The “at-will” nature of the employment
relationship with the Executive can only be altered by a written resolution approved by the Board. 
 5.
Non-Solicitation. 
 (a) Non-Solicit. The Executive agrees that during the term of the
Executive’s employment with the Company, and for a period of twelve (12) months immediately following the termination of the Executive’s employment with the Company for any reason, whether with

  
 5 

 
or without Cause or Good Reason, the Executive shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s or its affiliates’ employees or
consultants to terminate such employee’s or consultant’s relationship with the Company or its affiliates, or attempt to solicit, induce, recruit, encourage or take away employees or consultants of the Company or any of its affiliates,
either for the Executive or for any other person or entity. Further, during the Executive’s employment with the Company or any of its affiliates and at any time following termination of the Executive’s employment with the Company or any of
its affiliates for any reason, with or without Cause or Good Reason, the Executive shall not use any confidential information of the Company or any of its affiliates to attempt to negatively influence any of the Company’s or any of its
affiliates’ clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct such person’s or entity’s
purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company or any of its affiliates. 

(b) Specific Performance. In the event of the breach or threatened breach by the Executive of this Section 5,
the Company, in addition to all other remedies available to it at law or in equity, will be entitled to seek injunctive relief and/or specific performance to enforce this Section 5. 

6. Director and Officer Liability Insurance; Indemnification. During the term of the Executive’s employment hereunder, the
Executive shall be entitled to the same indemnification and director and officer liability insurance as the Company and its affiliates maintain for other corporate officers. 
 7. Proprietary Information and Inventions Assignment Agreement. The Executive has executed and delivered the Company’s standard Employee Proprietary Information and Inventions Assignment
Agreement or similar agreement and the Executive represents and warrants that the Executive shall continue to be bound and abide by such Employee Proprietary Information and Inventions Assignment Agreement or similar agreement. 

8. Attention to Duties; Conflict of Interest. While employed by the Company, the Executive shall devote the Executive’s full
business time, energy and abilities exclusively to the business and interests of the Company, and shall perform all duties and services in a faithful and diligent manner and to the best of the Executive’s abilities. The Executive shall not,
without the Company’s prior written consent, render to others services of any kind for compensation, or engage in any other business activity that would materially interfere with the performance of the Executive’s duties under this
Agreement. The Executive represents that the Executive has no other outstanding commitments inconsistent with any of the terms of this Agreement or the services to be rendered to the Company. While employed by the Company, the Executive shall not,
directly or indirectly, whether as a partner, employee, creditor, shareholder, or otherwise, promote, participate or engage in any activity or other business competitive with the Company’s business. The Executive shall not invest in any company
or business which competes in any manner with the Company, except those companies whose securities are listed on reputable securities exchanges in the United States or European Union. 

  
 6 

 9. Miscellaneous. 

(a) Severability. If any provision of this Agreement shall be found by any arbitrator or court of competent
jurisdiction to be invalid or unenforceable, then the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable and to the extent that to do so would not deprive one of the parties of the substantial benefit
of its bargain. Such provision shall, to the extent allowable by law and the preceding sentence, be modified by such arbitrator or court so that it becomes enforceable and, as modified, shall be enforced as any other provision hereof, all the other
provisions continuing in full force and effect. 
 (b) No Waiver. The failure by either party at any time
to require performance or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision
hereof shall not be taken or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party
against whom such waiver is sought to be enforced. 
 (c) Assignment. This Agreement and all rights
hereunder are personal to the Executive and may not be transferred or assigned by the Executive at any time. The Company may assign its rights, together with its obligations hereunder, to any parent, subsidiary, affiliate or successor, or in
connection with any sale, transfer or other disposition of all or substantially all of its business and assets; provided, however, that any such assignee assumes the Company’s obligations hereunder. 

(d) Withholding. All sums payable to the Executive hereunder shall be reduced by all federal, state, local and
other withholding and similar taxes and payments required by applicable law. 
 (e) Entire Agreement. This
Agreement, including the agreements referred to herein (which are deemed incorporated by reference herein) constitute the entire and only agreement and understanding between the parties governing the terms and conditions of employment of the
Executive with the Company and this Agreement supersedes and cancels any and all previous contracts, arrangements or understandings with governing the terms and conditions of the Executive’s employment by the Company. In the event of any
conflict between the terms of any other agreement between the Executive and the Company entered into prior to the Effective Date, the terms of this Agreement shall control. 

(f) Amendment. This Agreement may be amended, modified, superseded, cancelled, renewed or extended only by an
agreement in writing executed by both parties hereto. 
 (g) Headings. The headings contained in this
Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement. In this Agreement, the singular includes the plural, the plural included the singular, the masculine gender includes both male and
female referents, and the word “or” is used in the inclusive sense. 

  
 7 

 (h) Notices. Any notices provided hereunder must be in writing and
shall be deemed effective upon the earlier of personal delivery (including, personal delivery by facsimile transmission or the third day after mailing by first class mail) to the Company at its primary office location and to the Executive at his
address as listed on the Company payroll (which address may be changed by written notice). 
 (i)
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which, taken together, constitute one and the same agreement. 

(j) Governing Law, Forum Selection, Jury Waiver. This Agreement and the rights and obligations of the parties
hereto shall be construed in accordance with the laws of the State of California without giving effect to the principles of conflict of laws. Any action, suit or other legal proceeding that is commenced to resolve any matter arising under or
relating to any provision of this Agreement shall be commenced only in a court of the State of California (or, if appropriate, a federal court located within Southern District of California ), and the Company and the Executive each
consents to the jurisdiction of such a court. Both the Company and the Executive expressly waive any right that any party either has or may have to a jury trial of any dispute arising out of or in any way related to the Executive’s
employment with or termination from the Company. 
 [Remainder of Page Intentionally Left Blank] 

  
 8 

 IN WITNESS WHEREOF, the Company and the Executive have executed this Executive
Employment Agreement as of the date first above written. 
  

			
	PACIRA PHARMACEUTICALS, INC.:
		
	By:	 	/s/ David Stack
		 	 David Stack
 Chief
Executive Officer

	
	EXECUTIVE:
	
	/s/ William Lambert
	William Lambert

  
 9 

 EXHIBIT A 

PAYMENTS SUBJECT TO SECTION 409A 
 1. Subject to this Exhibit A, any severance payments and benefits that may be due under the Agreement shall begin only upon the date of the Executive’s “separation from service”
(determined as set forth below) which occurs on or after the termination of the Executive’s employment. The following rules shall apply with respect to distribution of the severance payments and benefits, if any, to be provided to the Executive
under the Agreement, as applicable: 
 (a) It is intended that each installment of the severance payments and benefits under the
Agreement provided under shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to
the extent specifically permitted or required by Section 409A. 
 (b) If, as of the date of the Executive’s
“separation from service” from the Company, the Executive is not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments or benefits shall be made on the dates and terms
set forth in the Agreement. 
 (c) If, as of the date of the Executive’s “separation from service” from the
Company, the Executive is a “specified employee” (within the meaning of Section 409A), then: 
 (i) Each
installment of the severance payments and benefits due under the Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Executive’s separation from service occurs, be paid
within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and
shall be paid at the time set forth in the Agreement; and 
 (ii) Each installment of the severance payments and benefits due
under the Agreement that is not described in this Exhibit A, Section 1(c)(i) and that would, absent this subsection, be paid within the six-month period following the Executive’s “separation from service” from the Company
shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period
and paid in a lump sum on the date that is six months and one day following the Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however,
that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a 

  

 
separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an
involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of the Executive’s second taxable year following the
taxable year in which the separation from service occurs. 
 2. The determination of whether and when the Executive’s separation from
service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Exhibit A , Section 2,
“Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code. 
 3. The Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions of the Agreement (including this Exhibit) are determined to
constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section. 

  
 2Loan and Security Agreement

  Exhibit 10.25 

LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT is made and dated as of November 24, 2010 and is entered into by and between PACIRA PHARMACEUTICALS, INC., a Delaware corporation, PACIRA PHARMACEUTICALS, INC., a
California corporation, and each of subsidiaries that execute a Joinder from time to time, (individually, a “Borrower” and, collectively, the “Borrowers”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation and
HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership (collectively, the “Lender”). 
 RECITALS

 A. Borrowers have requested a loan in an aggregate principal amount of up to Twenty-Six Million Two Hundred Fifty
Thousand Dollars ($26,250,000) (the “Term Loan”); and 
 B. Lender is willing to make the Term Loan on the terms and
conditions set forth in this Agreement. 
 AGREEMENT 

NOW, THEREFORE, Borrowers and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION 
 1.1 Unless
otherwise defined herein, the following capitalized terms shall have the following meanings: 
 “Account Control
Agreement(s)” means any agreement entered into by and among the Lender, a Borrower and a third party Bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment
Property and which grants Lender a perfected first priority security interest in the subject account or accounts. 
 “ACH
Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H. 
 “Advance”
means any funds advanced under this Agreement. 
 “Advance Date” means the funding date of any Advance. 

“Advance Request” means a request for an Advance submitted by a Borrower to Lender in substantially the form of Exhibit A.

 “Agreement” means this Loan and Security Agreement, as amended from time to time. 

“Assignee” has the meaning given to it in Section 11.14. 

“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed,
manufactured or sold by a Borrower or which such Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings,
technical data or technology that have been sold, licensed or distributed by such Borrower since its incorporation. 

 “Cash” means all cash and liquid funds. 

“Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or
series of related transactions) of a Borrower or any Subsidiary, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of a Borrower or any Subsidiary in which the holders of a Borrower or
Subsidiary’s outstanding shares immediately before consummation of such transaction or series of related transactions do not (together with any affiliates of such holders), immediately after consummation of such transaction or series of related
transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly
owned by such parent), in each case without regard to whether a Borrower or Subsidiary is the surviving entity, or (ii) sale or issuance by a Borrower of new shares of Preferred Stock of a Borrower to investors, none of whom are current
investors in a Borrower, shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is
wholly owned by such parent); provided, however, an Initial Public Offering shall not constitute a Change in Control or (iii) any of the chief executive officer or (before an Initial Public Offering) the chief financial officer of Borrower as
of the date hereof shall cease to be involved in the day to day management of the business of Borrower, and a successor of such officer reasonably acceptable to Lender is not appointed on terms reasonably acceptable to Lender within 180 days of such
cessation of such involvement. 
 “Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Commitment Fee” means $50,000, which fee was paid to Lender prior to the Closing Date, and shall be deemed fully earned on
such date regardless of the early termination of this Agreement. 
 “Confidential Information” has the meaning given
to it in Section 11.13. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect
liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or
discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued
for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to
protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course
of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the
maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support
arrangement. 
 “Copyright License” means any written agreement granting any right to use any Copyright or Copyright
registration, now owned or hereafter acquired by a Borrower or in which a Borrower now holds or hereafter acquires any interest. 

  
 2 

 “Copyrights” means all copyrights, whether registered or unregistered, held
pursuant to the laws of the United States, any State thereof, or of any other country. 
 “Deposit Accounts” means any
“deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit. 
 “ERISA” is the Employee Retirement Income Security Act of 1974, and its regulations, as amended and in effect from time to time. 

“Event of Default” has the meaning given to it in Section 9. 

“Facility Charge” is a fee equal to $328,125. 
 “Financial Statements” means the financial statements required to be delivered under Section 7.1. 
 “GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time. 
 “Guarantor” means, as of the Closing Date, any Person who signs the Guaranty. 
 “Guaranty” means the Guaranty in the form executed in connection with the Agreement by certain shareholders of a Borrower. 

“Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price of property or services
(excluding trade credit entered into in the ordinary course of business and not past due more than 90 days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by
notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 
 “Initial Public Offering” means the initial firm commitment underwritten offering of Borrower’s common stock pursuant to a registration statement under the Securities Act of 1933 (the
“Securities Act”) filed with, and declared effective by, the Securities and Exchange Commission. 
 “Insolvency
Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its
creditors, or proceedings seeking reorganization, arrangement, or other similar relief. 
 “Intellectual Property”
means all of a Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and a Borrower’s goodwill associated with
any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith. 
 “Interest Only Period” means the period from the Closing Date through August 31, 2011, provided at Borrowers’ option, confirmed in a written request by a Borrower, the Interest Only
Period shall mean the period from the Closing Date through November 30, 2011 if (i) the FDA accepts the EXPAREL New Drug Application for review and (ii) a Borrower receives at least $50,000,000 in net new cash proceeds from an Initial
Public Offering, equity, convertible debt or strategic partnership financing or any combination thereof; provided, further, that at a Borrower’s option, confirmed in a written request 

  
 3 

 
by Borrower, the Interest Only Period means the period from the Closing Date through February 28, 2012 if (x) conditions (i) and (ii) of this sentence are satisfied and, in
addition, (y) Borrower receives FDA approval of the EXPAREL New Drug Application on or before December 31, 2011. 

“Interest Rate” means either the Term Loan A Interest Rate or the Term Loan B Interest Rate, as applicable. 

“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any
Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person. 
 “Joinder Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G. 

“Lender” has the meaning given to it in the preamble to this Agreement. 

“Lender Expenses” are all audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and expenses)
for preparing, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to a Borrower. 

“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests. 

“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy,
lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest. 

“Loan” means the Advances made under this Agreement. 
 “Loan Documents” means this Agreement, the Notes, the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements, the Subordination Agreement, the
Guaranty, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (excluding the Warrant), as the same may from time to time be amended, modified, supplemented or restated. 

“Material Adverse Effect” means a material adverse effect upon: (i) the business, operations, properties, assets, or
condition (financial or otherwise) of a Borrower; or (ii) the ability of a Borrower to perform the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with
respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens; provided, however, that for the avoidance of doubt, any actual cash burn of Borrowers that is materially
consistent with the cash burn for the Borrowers described in the most recent operating plan of Borrowers delivered to Lenders as of the Closing Date and any subsequent operating plan approved by Lenders will not, in and of itself, constitute a
“Material Adverse Effect”. 
 “Material Agreement” means (i) any agreements or instruments relating to
the Subordinated Debt, (ii) the Royalty Agreements, (iii) any agreement to which a Borrower is a party involving the receipt of payment of amounts in the aggregate exceeding $500,000 per year, and (iv) any agreement to which a
Borrower is a party the termination of which would reasonably be expected to have a Material Adverse Effect. 

  
 4 

 “Maturity Date” means the last day of the month that is 33 months after the
expiration of the Interest Only Period. 
 “Maximum Rate” shall have the meaning assigned to such term in
Section 2.2. 
 “Note(s)” means a Term Note. 

“Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence
or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. 

“Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all
registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country. 
 “Permitted Indebtedness” means: (i) Indebtedness of a Borrower in favor of Lender arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing
Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $1,000,000 in principal outstanding at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness
does not exceed the lesser of the cost or fair market value of the Equipment financed with such Indebtedness; (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary
course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by
cash or cash equivalents and issued on behalf of a Borrower or a Subsidiary thereof in an amount not to exceed $200,000 at any time outstanding prior to an Initial Public Offering, and not to exceed $500,00 at any time outstanding after an Initial
Public Offering, (viii) other Indebtedness in an amount not to exceed $100,000 at any time outstanding, (ix) Indebtedness owing by any Borrower to another Borrower, provided that (a) each Borrower shall have executed and delivered to
the other Borrower a demand note to evidence such Indebtedness, which note shall be in form and substance reasonably satisfactory to Lenders and shall be pledged to Lenders pursuant to the Pledge Agreement and (b) such Indebtedness shall be
subordinated to the Secured Obligations pursuant to the subordination terms set forth in such note, and (c) no Event of Default would occur either before or after giving effect to any such indebtedness; (x) Indebtedness incurred in
connection with interest rate swaps incurred in the ordinary course of business; and (xi) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to
impose materially more burdensome terms upon a Borrower or its Subsidiary, as the case may be. 
 “Permitted
Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any
State thereof maturing within one year from the date of acquisition thereof, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either
Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, and
(d) money market accounts; (iii) repurchases of stock from former employees, directors, or consultants of a Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate
amount 

  
 5 

 
not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted in
connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the ordinary course of a Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the
ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of a Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis
of cash proceeds to employees, officers or directors relating to the purchase of capital stock of a Borrower pursuant to employee stock purchase plans or other similar agreements approved by a Borrower’s Board of Directors;
(viii) Investments consisting of travel advances in the ordinary course of business; (ix) Investments in newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement promptly
after their formation by a Borrower and execute such other documents as shall be reasonably requested by Lender; (x) Investments in Subsidiaries organized outside of the United States approved in advance in writing by Lender; (xi) joint
ventures, partnerships or strategic alliances consistent with the ordinary course of business in Borrower’s industry, provided that (i) any cash Investments by Borrower therein do not exceed $500,000 in the aggregate in any fiscal year and
(ii) prior to the Borrower receiving within any 12 month period occurring after the date hereof at least $50,000,000 in net new cash proceeds from an Initial Public Offering, equity offering convertible debt or strategic partnership financing
(which strategic partnership is not related to EXPAREL or any combination thereof the Borrower may not grant an exclusive license for the use or development of technology in the United States unless the Lenders have consented to the terms thereof
(or if no such consent is given, then the first proceeds arising out of the license shall be used to repay the Secured Obligations); (xii) Investments of Funds held exclusively in the Royalty Accounts, to the extent such Investments are made in
accordance with the terms and conditions of the Royalty Lockbox Agreement; (xiii) Investments made pursuant to any investment policy adopted by a Borrower after the Closing Date and approved by Lenders; (xiv) Investments by a Borrower in a
Borrower; and (xv) additional Investments that do not exceed $250,000 in the aggregate. 
 “Permitted Liens”
means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not
delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers,
warehousemen, landlords and other like Persons arising in the ordinary course of a Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments,
decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment
insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids,
tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar
bonds; (vii) Liens on Equipment, software or other intellectual property,or other capital assets (not including Inventory) constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause
(iii) of “Permitted Indebtedness”; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not
interfering in any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a 

  
 6 

 
matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance
premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory and common law rights of set-off and other similar
rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the
ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of
Permitted Indebtedness; (xv) Licenses that constitute Permitted Transfers; (xvi) Liens securing the Indebtedness permitted in clause (vii) of “Permitted Indebtedness”, and (xvii) Liens incurred in connection with the
extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the
existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase. 
 “Permitted Transfers” means (i) sales of Inventory in the normal course of business, (ii) the Transfer of Assigned Interests, as such term is defined in the Royalty Assignment
Agreement, pursuant to the terms and conditions of the Royalty Assignment Agreement, (iii) non-exclusive and exclusive licenses for the use of Intellectual Property in the ordinary course of business of the transferor so long as, with respect
to each such license (a) no Event of Default has occurred or is continuing at the time of such Transfer, (b) the license constitutes an arms-length transaction in the course of the transferor’s business (and in the case of any
exclusive license, made in connection with a bona fide transaction and approved by the board of directors of the transferor) and such license (other than any exclusive license made in connection with a bona fide transaction and approved by the board
of directors of the transferor) is not a sale or assignment of the transferor’s Intellectual Property and does not restrict such transferor’s ability to pledge, grant a security in or lien on, or assign or otherwise Transfer any
Intellectual Property (other than an otherwise Permitted Transfer), (c) in the case of an exclusive license or a non-exclusive license that must be approved by the board of directors of the transferor, the transferor delivers 10 days prior
written notice and a brief summary of the terms of the license to Lender, (d) in the case of an exclusive license or a non-exclusive license that must be approved by the board of directors of the transferor, the transferor delivers to Lender
copies of the final executed licensing documents in connection with the license promptly upon consummation of the license, (e) all royalties, milestone payments or other proceeds arising from the licensing agreement are paid to a deposit
account that is governed by an Account Control Agreement, and (f) in the case of an exclusive license of EXPAREL in the United States entered into before a Borrower receives at least $50,000,000 of proceeds from an equity offering, including an
Initial Public Offering or strategic partnership financing (which strategic partnership is not related to EXPAREL) or any combination thereof within a 12-month period, Lenders have consented to the terms thereof (or if no such consent is given, then
the first proceeds arising out of the license shall be used to repay the Secured Obligations) , (iv) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, and (v) other Transfers
of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year. 
 “Person” means
any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government. 

“Preferred Stock” means at any given time any equity security issued by a Borrower that has any rights, preferences or
privileges senior to a Borrower’s common stock. 

  
 7 

 “Prepayment Charge” shall have the meaning assigned to such term in
Section 2.4. 
 “Prime Rate” means the Prime Rate that appears from time to time in the Western Edition of The
Wall Street Journal. 
 “Receivables” means (i) all of a Borrower’s Accounts, Instruments, Documents,
Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights. 

“Royalty Agreements” means, collectively, the Royalty Assignment Agreement, the Royalty Security Agreement, and the Royalty
Lockbox Agreement. 
 “Royalty Assignment Agreement” means the Amended and Restated Royalty Interests Assignment
Agreement dated as of March 23, 2007 (as in existence on the date hereof and as certified to Lender by a Borrower, or as amended after the date hereof in accordance with Section 7.4) by and between Pacira CA, as seller, and Royalty
Securitization Trust I (the “Trust”) as purchaser, pursuant to which Pacira CA has sold and assigned to Trust the “Assigned Interests” (as defined in the Royalty Assignment Agreement). 

“Royalty Collateral” means the “Collateral”, as defined in the Royalty Security Agreement. 

“Royalty Lockbox Agreement” means the Amended and Restated Lockbox Agreement dated as of March 23, 2007 (as in existence
on the date hereof and as certified to Lender by a Borrower, or as amended in accordance with Section 7.4) by and among [Borrower], Deutsche Bank Trust Company in its capacity as custodian and JPMorgan Chase Bank, N.A. 

“Royalty Security Agreement” means the Amended and Restated Security Agreement dated as of March 23, 2007 (as in existence
on the date hereof and as certified to Lender by a Borrower, or as amended in accordance with Section 7.4, by and between [Borrower] and Trust, pursuant to which [Borrower] has granted to Trust a security interest in the Royalty Collateral.

 “SBA” shall have the meaning assigned to such term in Section 7.15. 

“SBIC” shall have the meaning assigned to such term in Section 7.15. 

“SBIC Act” shall have the meaning assigned to such term in Section 7.15. 

“Secured Obligations” means a Borrower’s obligations under this Agreement and any Loan Document, including any obligation
to pay any amount now owing or later arising. 
 “Subordinated Indebtedness” means Indebtedness subordinated to the
Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion, including, without limitation, the Indebtedness described on Exhibit A to the Subordination Agreement. 

“Subordination Agreement” means the subordination agreement among Borrower, Lender and the Creditors named therein dated as of
November 24, 2010. 
 “Subsequent Financing” means the closing of any equity financing that becomes effective
after the Closing Date and before an Initial Public Offering. 

  
 8 

 “Subsidiary” means an entity, whether corporate, partnership, limited liability
company, joint venture or otherwise, in which a Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 
 “Term Loan A Interest Rate” means for any day, the greater of (i) 10.25% or (ii) 10.25% plus the amount by which the Prime Rate exceeds 4.0%.; provided, however, that upon the release
of the Guaranty, the Term Loan A Interest Rate will mean for any day thereafter, the greater of (y) 11.0% or (z) 11.0% plus the amount by which the Prime Rate exceeds 4.0%. 

“Term Loan B Interest Rate” means for any day, the greater of (i) 12.65% or (ii)12.65% plus the amount by which the Prime
Rate exceeds 4.0%. 
 “Term Note” means a Promissory Note in substantially the form of Exhibits B and B-1. 

“Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or
hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Trademarks”
means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the
United States, any State thereof or any other country or any political subdivision thereof. 
 “UCC” means the Uniform
Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect
to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial
Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. 

“Warrant” means the warrant entered into in connection with the Loan. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,”
“subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any
accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied.
Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. 

SECTION 2. THE LOAN 
  

	 	2.1	Term Loan. 

 (a)
Advances. Subject to the terms and conditions of this Agreement, on the Closing Date, Lender shall make, and Borrowers shall draw, an Advance of $11,250,000 (the “Term Loan A Loan”) and an Advance of $15,000,000 (the “Term Loan
B Loan”). 

  
 9 

 (b) Advance Request. To obtain an Advance, a Borrower shall complete,
sign and deliver an Advance Request and Term Note to Lender. Lender shall fund the Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Advance is satisfied as of the requested Advance Date.

 (c) Interest. The principal balance of each Advance shall bear interest thereon from such Advance Date
at the Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Interest Rate will float and change on the day the Prime Rate changes from time to time. 

(d) Payment. During the Interest Only Period, Borrowers will pay interest on each Advance on the first business day
of each month, beginning the month after the Advance Date. Borrowers shall repay the aggregate Term Loan principal balance that is outstanding on the date the Interest Only Period expires in 33 equal monthly installments of principal and interest
beginning the first business day of the month after such expiration and continuing on the first business day of each month thereafter. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on
Maturity Date. Borrowers shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the a Borrower’s account as authorized on the ACH
Authorization on each payment date of all periodic obligations payable to Lender under each Term Note or Advance. 
 2.2
Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate
permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum
Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne
interest at the Maximum Rate, then such excess interest actually paid by a Borrower shall be applied as follows: first, to the payment of principal outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s
accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrowers. 

2.3 Default Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to five percent
(5%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional
fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c), plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and
shall bear interest on interest, compounded at the rate set forth in Section 2.1(c) or Section 2.2, as applicable. 

2.4 Prepayment. At its option upon at least 5 business days prior notice to Lender, a Borrower may prepay any part of the
outstanding Advances by paying the principal balance, all accrued and unpaid interest, together with a prepayment charge equal to 1.25% of the Advance amount being prepaid (the “Prepayment Charge”), provided (i) at any time the
Guaranty is in effect, Borrowers may not prepay any part of the Term Loan A Loan without Lender’s prior written consent if any amount is outstanding in respect of the Term Loan B Loan and (ii) at any time the Guaranty is not in effect, any
prepayment(s) shall be applied pro rata to the outstanding balances of the Term Loan A Loan and the Term 

  
 10 

 
Loan B Loan. Borrowers shall pay the Prepayment Charge upon any prepayment of the Secured Obligations arising out of the occurrence of an Event of Default. Borrowers agree that the Prepayment
Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances. 

2.5 End of Term Charge. On the earliest to occur of (i) the Maturity Date, (ii) the date that Borrowers prepay the
outstanding Secured Obligations in full, or (iii) the due and proper acceleration of the Secured Obligations, Borrowers shall pay Lender a charge of $630,000. Notwithstanding the required payment date of such charge, it shall be deemed earned
by Lender as of the Closing Date. 
 2.6 Termination of Guaranty. As long as an Event of Default is not then continuing,
a Borrower may elect to terminate the Guaranty upon the earliest to occur of (a) a Borrower’s receipt after the Closing Date of at least $75,000,000 in net new cash proceeds in any 12-month period from one or more of an Initial Public
Offering, an equity financing, or convertible debt financing or strategic partnership, or any combination thereof, or (b) (i) Borrower’s receipt after the Closing Date of at least $50,000,000 in net new cash proceeds from an Initial
Public Offering, equity financing, convertible debt or strategic partnership, or any combination thereof, in any 12-month period, and (ii) the FDA approves EXPAREL or (c) a Borrower completes an Initial Public Offering, and after giving
effect thereto, such Borrower has a market capitalization of at least $400,000,000 and a balance of unrestricted cash (other than Permitted Liens) of at least $50,000,000. Such termination shall be effective upon Lender’s receipt of a
Borrower’s notice to terminate, together with such evidence as Lender may reasonably request of the satisfaction of the occurrence of any of (a), (b), or (c). 
 SECTION 3. SECURITY INTEREST 
 3.1 As security for the prompt,
complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, each Borrower grants to Lender a security interest in all of such Borrower’s personal property now owned or hereafter acquired, including the
following (collectively, the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles; (e) Inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash;
(i) Goods; (j) Intellectual Property; and (k) other tangible and intangible personal property of such Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, such Borrower and wherever located;
and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing. Notwithstanding the foregoing, so long as and to
the extent that the terms and conditions of the Royalty Agreements prohibit a Borrower from granting a security interest in the Royalty Collateral to Lender (or so long as a default under any Royalty Agreement would result from such grant to
Lender), the grant of security interest under this Agreement shall not extend to and the term “Collateral” shall not include (i) the Royalty Collateral and (ii) any deposit accounts of such Borrower that are subject to the
Royalty Lockbox Agreement and are dedicated exclusively to the receipt of royalty payments resulting from the license of the DepoDur and DepoCyt products (such deposit accounts, the “Royalty Deposit Accounts”); provided, however, if
(x) the Royalty Agreements are terminated or (y) the Royalty Agreements are amended to permit such Borrower to grant a security interest in the Royalty Collateral to Lender, then the grant of security interest under this Agreement shall
automatically extend to, and the term “Collateral” shall automatically include, the Royalty Collateral and the Royalty Deposit Accounts. Further, notwithstanding any provision in this Agreement to the contrary, the grant of security
interest herein shall not extend to and the term “Collateral” shall not include (all of the following, together with the Royalty Collateral and the Royalty Deposit Accounts, the “Excluded Assets”): (i) more than 65% of the
issued and outstanding voting capital stock of any Subsidiary of Borrower that is incorporated or organized in a jurisdiction other than the United States or any state or territory thereof, to the extent that Lender’s taking a security interest
in more than 65% of 

  
 11 

 
such stock would cause Borrower to incur adverse tax consequences, (ii) any “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use
thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, and (iii) any license or contract to the extent and only to the extent that the granting of a security interest in such
license or contract is expressly prohibited by any applicable statute, law, or regulation, or would constitute a default under or a breach of such license or contract, as applicable, but only to the extent that such prohibition or default is
enforceable under applicable law (including without limitation Sections 9406, 9407 and 9408 of the UCC); provided that upon the termination or expiration of any such prohibition, such license or contract, as applicable, shall automatically be
subject to the security interest granted in favor of Lender hereunder and become part of the “Collateral”. 
 SECTION 4.
CONDITIONS PRECEDENT TO LOAN 
 The obligations of Lender to make the Loan hereunder are subject to the satisfaction
by Borrowers of the following conditions: 
 4.1 Advances. On or prior to the Closing Date, Borrowers shall have
delivered to Lender the following: 
 (a) executed originals of the Loan Documents, Account Control Agreements, a
legal opinion of Borrowers’ counsel, and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all
cases in form and substance reasonably acceptable to Lender; 
 (b) certified copy of resolutions of each
Borrower’s board of directors evidencing approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby; 

(c) certified copies of the Articles of Incorporation and Certificate of Incorporation and the Bylaws, as amended through
the Closing Date, of each Borrower, as applicable; 
 (d) a certificate of good standing for each Borrower from
its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 

(e) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this
Agreement, which amounts may be deducted from the initial Advance; 
 (f) an Intellectual Property Security
Agreement; 
 (g) the Guaranty; 

(h) the Subordination Agreement; and 

(i) such other documents as Lender may reasonably request. 

  
 12 

 4.2 All Advances. On each Advance Date: 

(a) Lender shall have received (i) an Advance Request and a Note for the relevant Advance as required by
Section 2.1(b), as applicable, each duly executed by a Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Lender may reasonably request. 

(b) The representations and warranties set forth in this Agreement and in Section 5 shall be true and correct in all
material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 

(c) Each Borrower shall be in compliance in all material respects with all the terms and provisions set forth herein and
in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing. 

(d) Each Advance Request shall be deemed to constitute a representation and warranty by Borrowers on the relevant Advance
Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request. 
 4.3 No Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event
of Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 
 SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 
 Each Borrower
represents and warrants that: 
 5.1 Corporate Status. Such Borrower is a corporation duly organized, legally existing and
in good standing under the laws of the State of its incorporation, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the
failure to be qualified could reasonably be expected to have a Material Adverse Effect. Such Borrower’s present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and
other information are correctly set forth in Exhibit C, as may be updated by such Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date. 

5.2 Collateral. Such Borrower owns the Collateral free of all Liens, except for Permitted Liens. Such Borrower has the power and
authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations. 
 5.3 Consents;
Conflicts. Such Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan Documents, and Borrower’s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of
Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of
Borrower’s Certificate or Articles of Incorporation (as applicable), bylaws, or any material law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not
violate any Material Agreement or require the consent or approval of any other Person. The individual or individuals executing the Loan Documents and the Warrant are duly authorized to do so. 

  
 13 

 5.4 Material Adverse Effect. No event that has had or would reasonably be expected to
have a Material Adverse Effect has occurred and is continuing. Such Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect. 

5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at
law or in equity or by or before any governmental authority now pending or, to the knowledge of such Borrower, threatened in writing against or affecting such Borrower or its property that, if adversely determined would reasonably be expected to
have a Material Adverse Effect. 
 5.6 Laws. Such Borrower is not in violation of any law, rule or regulation, or in
default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Such Borrower is not in default in any manner under any
provision of any agreement or instrument evidencing indebtedness, or any other material agreement to which it is a party or by which it is bound, and which default would reasonably be expected to have a Material Adverse Effect. 

5.7 Information Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule furnished,
by or on behalf of a Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained, contains or will contain any material misstatement of fact or omitted, omits or will omit to state any material
fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not misleading at the time such statement was made or deemed made. Additionally, any and all financial or business
projections provided by such Borrower to Lender shall be (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided to such Borrower’s
Board of Directors. 
 5.8 Taxes. Except as described on Schedule 5.8, such Borrower has (a) filed all federal,
state and local tax returns that it is required to file, (b) duly paid or fully reserved for all material taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such
returns, and (c) paid or fully reserved for any material tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings).

 5.9 Intellectual Property Claims. Such Borrower is the sole owner of, or otherwise has the right to use, the
Intellectual Property. Except as described on Schedule 5.9, (i) each of the material issued Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or
unenforceable, in whole or in part, and (iii) no claim has been made to such Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D is a true, correct and complete list of each of
Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together with application or
registration numbers, as applicable, owned by such Borrower or any Subsidiary, in each case as of the Closing Date. Such Borrower is not in material breach of, nor has such Borrower failed to perform any material obligations under, any of the
foregoing contracts, licenses or agreements and, to such Borrower’s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. 

5.10 Intellectual Property. Except as described on Schedule 5.10, such Borrower has, or in the case of any proposed business, will
have, all material rights with respect to Intellectual Property 

  
 14 

 
necessary in the operation or conduct of such Borrower’s business as currently conducted and proposed to be conducted by such Borrower. Without limiting the generality of the foregoing, and
in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC,- and except as described on Schedule 5.10, Borrower has the right, to the extent required to operate such Borrower’s business, to freely
transfer, license or assign Intellectual Property without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid
licenses, all software development tools, library functions, compilers and all other third-party software and other items that are used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of
Borrower Products. 
 5.11 Borrower Products. Except as described on Schedule 5.11, no Intellectual Property owned by
such Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of such Borrower, threatened litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign
office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner such Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There
is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates such Borrower to grant licenses or ownership interest in any future Intellectual
Property related to the operation or conduct of the business of Borrower or Borrower Products. Such Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning such
Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or
beneficial ownership with respect thereto nor, to such Borrower’s knowledge, is there a reasonable basis for any such claim. Neither such Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products
infringes the Intellectual Property or other rights of others. 
 5.12 Financial Accounts. Exhibit E, as may be updated
by the Borrowers in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which a Borrower or any Subsidiary maintains Deposit Accounts and
(b) all institutions at which such Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which
the account is held, a description of the purpose of the account, and the complete account number therefor. 
 5.13 Employee
Loans. Except as permitted by Section 7.8, such Borrower has no outstanding loans to any employee, officer or director of such Borrower nor has such Borrower guaranteed the payment of any loan made to an employee, officer or director of
such Borrower by a third party. 
 5.14 Capitalization and Subsidiaries. Each Borrower’s capitalization as of the
Closing Date is set forth on Schedule 5.14 annexed hereto. No Borrower owns any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by a Borrower in a written
notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary. 

  
 15 

 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1 Coverage. Each Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form,
against risks customarily insured against in such Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms
of the indemnification agreement found in Section 6.3. Each Borrower shallt maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence. Each Borrower has and shall maintain a minimum of $2,000,000 of
directors and officers’ insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, such Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring
against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. Borrower shall also carry and
maintain a fidelity insurance policy in an amount not less than $100,000. 
 6.2 Certificates. Each Borrower shall
deliver to Lender certificates of insurance that evidence such Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Such Borrower’s insurance certificate shall
state Lender is an additional insured for commercial general liability, an additional insured and a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for
property insurance and additional insured for liability insurance for any future insurance that such Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and
lender’s loss payable endorsements for all risk property damage insurance and fidelity. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation or any other change
adverse to Lender’s interests (except with respect to non-payment, in which case 10 days advance notice is sufficient). Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver of any of Lender’s
rights, all of which are reserved. 
 6.3 Indemnity. Each Borrower agrees to indemnify and hold Lender and its officers,
directors, employees, agents, in-house attorneys, representatives and shareholders (each, an Indemnitee”) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages
and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be
instituted or asserted against or incurred by an Indemnitee as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or
arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting from the
Indemnitee’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent jurisdiction. In no event shall any Indemnitee be liable on any theory of liability for any special, indirect, consequential or
punitive damages. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by
the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement; provided, however, that (i) with respect to such liabilities imposed originally and independently on Lenders,
Lenders shall notify a Borrower of any such liabilities within 180 days of the initial date Lenders had actual knowledge, or should have had knowledge, of a Lender’s direct exposure to such liabilities, and (ii) with respect to all other
such liabilities not described in subsection (i), Lenders shall notify Borrower of any such liabilities within 180 days of the initial date a Lender has actual knowledge of its direct exposure to such liabilities. 

  
 16 

 SECTION 7. COVENANTS OF BORROWER 

Each Borrower agrees as follows: 
 7.1 Financial Reports. Such Borrower shall furnish the following to Lender: 
 (a) As soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated
and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against such
Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, all certified by such Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance
with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial
statements; 
 (b) As soon as practicable (and in any event within 45 days) after the end of each calendar
quarter, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows
accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against such Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, certified
by such Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year end
adjustments; 
 (c) as soon as practicable, and in any event within 150 days (90 days if Borrower is required to
file reports under the Securities Exchange Act of 1934, as amended) after the end of each fiscal year, unqualified audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including
balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and
reasonably acceptable to Lender, accompanied by any management report from such accountants; 
 (d) as soon as
practicable (and in any event within 30 days) after the end of each calendar month and calendar quarter, a Compliance Certificate in the form of Exhibit F; 
 (e) promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower has made available to holders of its Preferred Stock and
copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;

 (f) before the Initial Public Offering, promptly following the delivery of the same-to its directors, copies
of all notices, minutes, consents and other materials that Borrower provides to its directors in connection with meetings of the Board of Directors, and minutes of such meeting, provided Borrower may exclude from such delivery any materials, the
disclosure of which could constitute or effect a waiver of the attorney-client privilege; and 

  
 17 

 (g) financial and business projections, as well as budgets, operating plans
and other financial information reasonably requested by Lender. 
 The executed Compliance Certificate may be
sent via facsimile to Lender at (650) 473-9194 or via e-mail to pshah@herculestech.com. All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to
financialstatements@herculestech.com with a copy to pshah@herculestech.com provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: (866) 468-8916,
attention Chief Credit Officer. 
 7.2 Management Rights. Each Borrower shall permit any representative that Lender
authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of such Borrower at reasonable times and upon reasonable notice during normal business hours
(but in any event no more than twice in any 12-month period unless an Event of Default has occurred and is continuing). In addition, any such representative shall have the right to meet with management and officers of such Borrower to discuss such
books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of such Borrower concerning significant business issues affecting Borrower. Such
consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R
Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s
management or policies. 
 7.3 Further Assurances. Each Borrower shall from time to time execute, deliver and file, alone
or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other necessary documents to perfect or give the highest priority to Lender’s Lien on the Collateral (subject to Permitted
Liens). Each Borrower shall from time to time procure any instruments or documents as may be requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and protect the Liens
granted hereby and thereby. In addition, and for such purposes only, such Borrower authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements, security
agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall, in its reasonable business judgment, protect and defend
Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens. 
 7.4 Amendments to Other Agreements. No Borrower may amend, modify or waive any provision of (a) any Royalty Agreement to modify (i) the scope of the Royalty Collateral or
(ii) Section 5.11(c)(iv) of the Royalty Assignment Agreement, (b) any of Borrower’s organizational documents, unless the net effect of such amendment, modification or waiver is not adverse in any material respect to Borrower or
Lender (it being agreed for the avoidance of doubt that any amendment or modification to the organization documents of Borrower to permit the issuance of equity on terms and conditions that are not prohibited under this Agreement shall not be
considered adverse to Borrower or Lender), or (c) any document relating to any of the Subordinated Indebtedness, in each case, without the prior written consent of Lender. For clarity, this Section does not restrict conversion of any
Subordinated Indebtedness into equity, or any amendment to the organization documents of Borrower to increase the number of authorized shares of Borrower, in each case in connection with the IPO. 

  
 18 

 7.5 Indebtedness. Such Borrower shall not create, incur, assume, guarantee or be or
remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on such Borrower an obligation to prepay any Indebtedness, except for
the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion. 
 7.6 Collateral. Such Borrower shall at all times keep the Collateral and all other property and assets used in such Borrower’s business or in which such Borrower now or hereafter holds any
interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting the Collateral, such other property and assets, or any Liens thereon. Such
Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and such Borrower shall cause its Subsidiaries at all times to keep
such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets. Such
Borrower shall not enter into any agreement (other than the Royalty Agreements, Permitted Licenses and Permitted Transfers) in which a negative pledge in the Intellectual Property is granted to any Person other than Lender. 

7.7 Investments. Such Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or
permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.8 Restricted Payments. Such Borrower
shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in
each case the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest, and in any case does not exceed $200,000 in any fiscal year for all such repurchases or redemptions, or (b) declare
or pay any cash dividend or make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors or
guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or (d) waive, release or forgive any indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate, or
(e) make any payments to the Trust other than scheduled periodic payments required to be made pursuant to the terms and conditions of the Royalty Assignment Agreement, or (f) permit any Subsidiary to be a party to, or bound by, any
agreement that restricts such Subsidiary from paying dividends or otherwise distributing property to Borrower. 
 7.9
Transfers. Except for Permitted Transfers, such Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of their
assets. 
 7.10 Mergers or Acquisitions. Such Borrower shall not merge or consolidate, or permit any of its Subsidiaries
to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or substantially all
of the capital stock or property of another Person. 
 7.11 Taxes. Such Borrower and its Subsidiaries shall pay when due
all taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against such Borrower, Lender or the Collateral or upon Borrower’s ownership,

  
 19 

 
possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal
property tax returns in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP. 

7.12 Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of
formation without 10 days’ prior written notice to Lender. Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business
unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (w) Permitted
Transfers, (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, (z) relocations of Collateral from a location described on Exhibit C to
another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party bailee, it has
delivered a bailee agreement in form and substance reasonably acceptable to Lender. 
 7.13 Deposit Accounts. Neither
Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except (i) with respect to which Lender has an Account Control Agreement and (ii) constituting Royalty Accounts. 

7.14 Subsidiaries. Such Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days
of formation, shall cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement. 
 7.15 Compliance. Such Borrower shall not, and Borrower shall not permit any of its Subsidiaries to, fail to comply in any material respect with, or violate in any material respect, any law or
regulation applicable to it. 
 7.16 SBA. Lender has received a license from the U.S. Small Business Administration
(“SBA”) to extend loans as a small business investment company (“SBIC”) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations (collectively, the “SBIC Act”). Portions of the
loan to Borrower will be made under the SBA license and the SBIC Act. Addendum 1 to this Agreement outlines various responsibilities of Lender and Borrower associated with an SBA loan, and such Addendum 1 is hereby incorporated in this Agreement

 7.17 EXPAREL. By December 14, 2010, Borrower shall deliver to Lenders written confirmation by the FDA of its
acceptance of the EXPAREL New Drug Application. 
 SECTION 8. RIGHT TO INVEST 

8.1 Subject to applicable securities laws and regulatory requirements, Lender or its assignee or nominee shall have the right, in its
discretion, to participate in any Subsequent Financing in an amount of up to $2,000,000 in the aggregate for all Subsequent Financings (provided Lender shall have the same right to participate pro rata in future financings as are granted to other
investors in a Subsequent Financing in which Lender participated) on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing. 

  
 20 

 SECTION 9. EVENTS OF DEFAULT 

The occurrence of any one or more of the following events shall be an Event of Default: 

9.1 Payments. A Borrower fails to pay any amount due under this Agreement, the Notes or any of the other Loan Documents on the due
date, and in each case such default continues for more than 3 business days after the due date thereof; or 
 9.2
Covenants. A Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, the Notes, or any of the other Loan Documents , and (a) with respect to a default under any covenant under this
Agreement (other than under Sections 6, 7.5, 7.6, 7.7, 7.8 or 7.9) such default continues for more than ten (10) business days after the earlier of the date on which (i) Lender has given notice of such default to a Borrower and (ii) a
Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.5, 7.6, 7.7, 7.8 or 7.9, the occurrence of such default; or 
 9.3 Material Adverse Effect. A circumstance has occurred that would reasonably be expected to have a Material Adverse Effect; or 

9.4 Other Loan Documents. The occurrence of any default under any Loan Document or any other agreement between Borrower and Lender
and such default continues for more than ten (10) days after the earlier of (a) Lender has given notice of such default to a Borrower, or (b) a Borrower has actual knowledge of such default; or 

9.5 Representations. Any representation or warranty made by a Borrower in any Loan Document or in the Warrant shall have been
false or misleading in any material respect when made; or 
 9.6 Insolvency. A Borrower
(A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents; or (iii) shall file a voluntary petition in
bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation
pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of a Borrower or of all or any substantial part (i.e., 33 1/3% or more) of the assets or property of Borrower; or (vi) shall
cease operations of its business as its business has normally been conducted for 3 consecutive business days, or terminate substantially all of its employees; or (vii) a Borrower or its directors or majority shareholders shall take any action
initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) thirty (30) days shall have expired after the commencement of an involuntary action against a Borrower seeking reorganization,
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the
business of a Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) a Borrower shall file any answer admitting or not
contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or
(v) thirty (30) days shall have expired after the appointment, without the consent or acquiescence of a Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without
such appointment being vacated, or (C) a Borrower becomes insolvent; or 

  
 21 

 9.7 Attachments; Judgments. Any portion of a Borrower’s assets having a value in
excess of $250,000 is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $500,000, or a Borrower is enjoined or in any way
prevented by court order from conducting any material part of its business; or 
 9.8 Other Obligations. The occurrence
of any default under any agreement or obligation of a Borrower involving any Indebtedness in excess of $500,000, or the occurrence of any default under any agreement or obligation of Borrower that could reasonably be expected to have a Material
Adverse Effect; or 
 9.9 Royalty Agreements. A “Purchase Option Event”, as defined in the Royalty Assignment
Agreement, shall have occurred and the Trust shall have commenced the exercise of the purchase option pursuant to Section 5.07 of the Royalty Assignment Agreement (or the Trust shall have given written notice to a Borrower of its intention to
exercise such purchase option), or any “Event of Default”, as such term is defined in the Royalty Security Agreement, shall have occurred and the Trust shall have commenced the exercise of remedies under the Royalty Security Agreement (or
the Trust shall have given written notice to a Borrower of its intention to exercise such remedies); or 
 9.10 Guaranty;
Subordination Agreement. Any of the circumstances set forth in Section 9.6 shall exist in respect of any Guarantor, or if any Guarantor breaches any of its obligations under the Guaranty (and the expiration of any cure period under this
Section 9 applicable to a comparable breach), or if any provision of the Guaranty shall fail to be valid and binding on, or enforceable against, a Guarantor, or if any subordination provision set forth in the Subordination Agreement shall, in
whole or in part, terminate or otherwise fail or cease to be valid and binding on, or enforceable against, any agent for or holder of the Subordinated Indebtedness (or such person shall so state in writing). 

SECTION 10. REMEDIES 
 10.1 General. Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations
together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.6, the Notes and all of the Secured Obligations shall
automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender may notify any of a Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such
account on a Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan
Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy,
utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not exclusive. 

10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or
from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender
may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Each Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower.
Lender may require Borrower to assemble the Collateral and make it available to Lender at a 

  
 22 

 
place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied
by Lender in the following order of priorities: 
 First, to Lender in an amount sufficient to pay in full Lender’s costs
and professionals’ and advisors’ fees and expenses; 
 Second, to Lender in an amount equal to the then unpaid amount
of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 
 Finally, after the full and final payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to a Borrower or its representatives or as a court of
competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the
Collateral if it complies with the obligations of a secured party under the UCC. 
 10.3 No Waiver. Lender shall be under
no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and each Borrower waives all rights, if any, to require Lender to marshal any Collateral. 

10.4 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers and
remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers
and remedies of Lender. 
 SECTION 11. MISCELLANEOUS 
 11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this
Agreement. 
 11.2 Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval,
declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall
be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or
(ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows: 

(a)     If to Lender: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
 HERCULES TECHNOLOGY III,
L.P. 
 Legal Department 
 Attention: Chief Legal Officer and Parag Shah 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Telephone: 650-289-3068 

  
 23 

  

	 	(b)	If to a Borrower: 

 PACIRA
PHARMACEUTICALS, INC. 
 Attention: Mr. James Scibetta 

5 Sylvan Way 

Parsippany, NJ 07054 
 Facsimile: 
 Telephone: 

or to such other address as each party may designate for itself by like notice. 

11.3 Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral,
with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated October 27, 2010). None of the terms of this Agreement, the Notes or any of the other Loan Documents may be amended except by an
instrument executed by each of the parties hereto. 
 11.4 No Strict Construction. The parties hereto have participated
jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 11.5 No
Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No
omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by a Borrower at any time designated, shall be a waiver of any such right or remedy
to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter. 
 11.6
Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the
execution and delivery of this Agreement and the expiration or other termination of this Agreement. 
 11.7 Successors and
Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). No Borrower may assign its obligations under this Agreement, the Notes or any of
the other Loan Documents without Lender’s express prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without
prior notice to Borrowers, and all of such rights shall inure to the benefit of Lender’s successors and assigns. 

  
 24 

 11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been
negotiated and delivered to Lender in the State of California, and shall have been accepted by Lender in the State of California. Payment to Lender by a Borrower of the Secured Obligations is due in the State of California. This Agreement, the Notes
and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of
Section 11.10 is not applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal court located in the State of California. By execution and delivery of this
Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of
California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Notes or the
other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed
effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other
jurisdiction. 
 11.10 Mutual Waiver of Jury Trial / Judicial Reference. 

(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved
by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH BORROWER AND
LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE
OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than a Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between a
Borrower and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 

(b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable, the parties agree that
all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding
Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in
Section 11.9, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference. 

  
 25 

 11.11 Professional Fees. Each Borrower promises to pay Lender’s fees and
expenses necessary to finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’
and other professionals’ fees and expenses (including fees and expenses of in-house counsel) incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement
of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral
or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and
(g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding
or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof. 
 11.12
Publicity. Lender may use a Borrower’s name and logo, and include a brief description of the relationship between such Borrower and Lender, in Lender’s marketing materials provided such use does not violate the Securities Act and
provided Borrower has consented to such use at all times prior to the Initial Public Offering, such consent not to be unreasonably withheld. 
 11.13 Confidentiality. Lender acknowledges that certain items of Collateral and information provided to Lender by a Borrower are confidential and proprietary information of Borrower, if and to the
extent such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the “Confidential Information”). Accordingly, Lender agrees that any
Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s security interest in the Collateral shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part,
without the prior written consent of such Borrower, except that Lender may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its
sole discretion determines that any such party should have access to such information in connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential
Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information;
(b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if
required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or law applicable to Lender;
(f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral after default; (g) to any participant or
assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior
consent of such Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents. 

11.14 Assignment. Each Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder
and under the Note(s) and Loan Documents to any person or entity (an “Assignee”). After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with
all rights, powers and remedies 

  
 26 

 
of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such
assignment by Lender shall relieve Borrower of any of its obligations hereunder. Each Lender agrees that in the event of any transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the principal of the Note(s), which
shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon. 

11.15 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue to
be effective if any petition is filed by or against a Borrower for liquidation or reorganization, if a Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant
part of a Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the
case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is
recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral had not been made.
In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have
been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 
 11.16
Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed
an original, but all of which counterparts shall constitute but one and the same instrument. 
 11.17 No Third Party
Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically
provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely between the Lender and the Borrower 
 11.18 Surety Waivers. Each Borrower may, acting singly, request Advances. Each Borrower appoints the other Borrower as agent for the other for all purposes hereunder, including with respect to
requesting Advances hereunder. Each Borrower shall be jointly and severally obligated to repay all Advances made hereunder, regardless of which Borrower actually receives said Advance, as if each Borrower hereunder directly received all
Advances. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, including, without limitation, the benefit of California Civil Code Section 2815 permitting revocation as to future
transactions and the benefit of California Civil Code Sections 1432, 2809, 2810, 2819, 2839, 2845, 2847, 2848, 2849, 2850, and 2899 and 3433, and (b) any right to require Lender to: (i) proceed against any Borrower or any other person;
(ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Lender may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial
or non-judicial sale) without affecting any Borrower’s liability. Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including,
without limitation, any law subrogating Borrower to the rights of Lender under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now

  
 27 

 
or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all
rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise. Any agreement
providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust
for Lender and such payment shall be promptly delivered to Lender for application to the Obligations, whether matured or unmatured. 
 (SIGNATURES TO FOLLOW) 

  
 28 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

							
		 		 	BORROWER:
			
		 		 	PACIRA PHARMACEUTICALS, INC., a Delaware corporation
				
		 		 	Signature:	 	 /s/ James Scibetta

				
		 		 	Print Name:	 	 James Scibetta

				
		 		 	Title:	 	 Chief Financial Officer

			
		 		 	PACIRA PHARMACEUTICALS, INC., a California corporation
				
		 		 	Signature:	 	 /s/ James Scibetta

				
		 		 	Print Name:	 	 James Scibetta

				
		 		 	Title:	 	 Chief Financial Officer

				
	Accepted in Palo Alto, California:	 		 		 	
			
		 		 	LENDER:
			
		 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	Signature:	 	 /s/ K. Nicholas Martitsch

				
		 		 	Print Name:	 	 K. Nicholas Martitsch

				
		 		 	Title:	 	 Associate General Counsel

			
		 		 	 HERCULES TECHNOLOGY III, L.P.,
 a Delaware limited partnership

			
		 		 	By:         Hercules Technology SBIC Management, LLC, its General Partner
			
		 		 	By:         Hercules Technology Growth Capital, Inc., its
Manager

									
					
		 		 		  	By:	 	 /s/ K. Nicholas Martitsch

		 		 		  	Name:	 	 K. Nicholas Martitsch

		 		 		  	Its:	 	 Associate General Counsel

  
 1 

 Table of Addenda, Exhibits and Schedules 

 

			
		
	Addendum 1:	  	SBA Provisions
		
	Exhibit A:	  	 Advance Request
 Attachment to
Advance Request

		
	Exhibit B:	  	Term Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Debit Authorization Agreement
		
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.5	  	Actions Before Governmental Authorities
	Schedule 5.8	  	Tax Matters
	Schedule 5.9	  	Intellectual Property Claims
	Schedule 5.10	  	Intellectual Property
	Schedule 5.11	  	Borrower Products
	Schedule 5.14	  	Capitalization

  
 1 

 ADDENDUM 1 to LOAN AND SECURITY AGREEMENT 

(a) Borrower’s Business. For purposes of this Addendum 1, Borrower shall be deemed to include its “affiliates” as defined in
Title 13 Code of Federal Regulations Section 121.103. Borrower represents and warrants to Lender (as of the Closing Date and for a period of one year thereafter) and covenants to Lender as follows: 

 

	 	1.	Size Status. Borrower does not have in excess of 500 employees as of the Closing Date; 

 

	 	2.	No Relender. Borrower’s primary business activity does not involve, directly or indirectly, providing funds to others, purchasing debt obligations, factoring,
or long-term leasing of equipment with no provision for maintenance or repair; 

  

	 	3.	No Passive Business. Borrower is engaged in a regular and continuous business operation (excluding the mere receipt of payments such as dividends, rents, lease
payments, or royalties). Borrower’s employees are carrying on the majority of day to day operations. Borrower will not pass through substantially all of the proceeds of the Loan to another entity; 

 

	 	4.	No Real Estate Business. Borrower is not classified under Major Group 65 (Real Estate) or Industry No. 1531 (Operative Builders) of the SIC Manual. The
proceeds of the Loan will not be used to acquire or refinance real property unless Borrower (x) is acquiring an existing property and will use at least 51 percent of the usable square footage for its business purposes; (y) is building or
renovating a building and will use at least 67 percent of the usable square footage for its business purposes; or (z) occupies the subject property and uses at least 67 percent of the usable square footage for its business purposes.

  

	 	5.	No Project Finance. Borrower’s assets are not intended to be reduced or consumed, generally without replacement, as the life of its business progresses, and the
nature of Borrower’s business does not require that a stream of cash payments be made to the business's financing sources, on a basis associated with the continuing sale of assets (e.g., real estate development projects and oil and gas
wells). The primary purpose of the Loan is not to fund production of a single item or defined limited number of items, generally over a defined production period, where such production will constitute the majority of the activities of Borrower
(e.g., motion pictures and electric generating plants). 

  

	 	6.	No Farm Land Purchases. Borrower will not use the proceeds of the Loan to acquire farm land which is or is intended to be used for agricultural or forestry purposes,
such as the production of food, fiber, or wood, or is so taxed or zoned. 

  

	 	7.	No Foreign Investment. The proceeds of the Loan will not be used substantially for a foreign operation. At the time of the Loan, Borrower will not have more
than 49 percent of its employees or tangible assets located outside the United States. The representation in this subsection (7) is made only as of the date hereof and shall not continue for one year as contemplated in the first sentence
of this Section 1. 

 (b) Small Business Administration Documentation. Lender acknowledges that Borrower
completed, executed and delivered to Lender SBA Forms 480, 652 and 1031 (Parts A and B) together with a business plan showing Borrower’s financial projections (including balance sheets and income and cash flows statements) for the period
described therein and a written statement (whether included in the purchase agreement or pursuant to a separate statement) from Lender regarding its intended use of proceeds from 

  
 1 

 
the sale of securities to Lender (the “Use of Proceeds Statement”). Borrower represents and warrants to Lender that the information regarding Borrower and its affiliates set forth
in the SBA Form 480, Form 652 and Form 1031 and the Use of Proceeds Statement delivered as of the Closing Date is accurate and complete. 
 (c) Inspection. The following covenants contained in this Section (c) are intended to supplement and not to restrict the related provisions of the Loan
Documents. Subject to the preceding sentence, Borrower will permit, for so long as Lender holds any debt or equity securities of Borrower, Lender or its representative, at Lender’ expense, and examiners of the SBA to visit and inspect the
properties and assets of Borrower, to examine its books of account and records, and to discuss Borrower’s affairs, finances and accounts with Borrower’s officers, senior management and accountants, all at such reasonable times as may be
requested by Lender or the SBA. 
 (d) Annual Assessment. Promptly after the end of each calendar year (but in any event
prior to February 28 of each year) and at such other times as may be reasonably requested by Lender, Borrower will deliver to Lender a written assessment of the economic impact of Lender’ investment in Borrower, specifying the full-time
equivalent jobs created or retained in connection with the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic benefits resulting from the investment (such as technology
development or commercialization, minority business development, or expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lender’s SBA Form 468. Lender will assist Borrower
with preparing such assessment. In addition to any other rights granted hereunder, Borrower will grant Lender and the SBA access to Borrower’s books and records for the purpose of verifying the use of such proceeds. Borrower also will
furnish or cause to be furnished to Lender such other information regarding the business, affairs and condition of Borrower as Lender may from time to time reasonably request. 
 (e) Use of Proceeds. Borrower will use the proceeds from the Loan only for general working capital purposes. Borrower will deliver to Lender from time to time promptly following Lender’s
request, a written report, certified as correct by Borrower's Chief Financial Officer, verifying the purposes and amounts for which proceeds from the Loan have been disbursed. Borrower will supply to Lender such additional information and
documents as Lender reasonably requests with respect to its use of proceeds and will permit Lender and the SBA to have access to any and all Borrower records and information and personnel as Lender deems necessary to verify how such proceeds have
been or are being used, and to assure that the proceeds have been used for the purposes specified in this Section 7.16. 
 (f)
Activities and Proceeds. Neither Borrower nor any of its affiliates (if any) will engage in any activities or use directly or indirectly the proceeds from the Loan for any purpose for which a small business investment company is prohibited
from providing funds by the SBIC Act, including 13 C.F.R. §107.720. Without obtaining the prior written approval of Lender, Borrower will not change within 1 year of the date hereof, Borrower’s current business activity to a
business activity which a licensee under the SBIC Act is prohibited from providing funds by the SBIC Act. 
 (g) Redemption Provisions.
Notwithstanding any provision to the contrary contained in the Certificate of Incorporation of Borrower, as amended from time to time (the “Charter”), if, pursuant to the redemption provisions contained in the Charter, Lender is
entitled to a redemption of its Warrant, such redemption (in the case of Lender) will be at a price equal to the redemption price set forth in the Charter (the “Existing Redemption Price”). If, however, Lender delivers written notice to
Borrower that the then current regulations promulgated under the SBIC Act prohibit payment of the Existing Redemption Price in the case of an SBIC (or, if applied, the Existing Redemption Price would cause the Series C Preferred Stock to lose its
classification as an “equity security” and Lender has determined that such classification 

  
 2 

 
is unadvisable), the amount Lender will be entitled to receive shall be the greater of (i) fair market value of the securities being redeemed taking into account the rights and preferences
of such securities plus any costs and expenses of the Lender incurred in making or maintaining the Warrant, and (ii) the Existing Redemption Price where the amount of accrued but unpaid dividends payable to the Lender is limited to Borrower's
earnings plus any costs and expenses of the Lender incurred in making or maintaining the Warrant; provided, however, the amount calculated in subsections (i) or (ii) above shall not exceed the Existing Redemption Price. 

(h) Cost of Money. Notwithstanding any provision to the contrary contained in the Loan Documents, all interest and fees charged pursuant to the
Loan Documents shall comply with the provisions of 13 C.F.R. § 107.855, including, without limitation, that such amounts shall not exceed the Cost of Money ceiling (as defined hereafter). The current Cost of Money ceiling for this Loan is
14.5%, not including the valuation of the Warrant. 
 (i) Compliance and Resolution. Borrower agrees that a failure to comply with
Borrower’s obligations under this Addendum, or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Lender believes that there is a substantial risk of such assertion) that Lender and its
affiliates are not entitled to hold, or exercise any significant right with respect to, any securities issued to Lender by Borrower, will, subject to the provisions in the remainder of this clause (i), constitute a breach of the obligations of
Borrower under the financing agreements between Borrower and Lender. In the event of (i) a failure to comply with Borrower’s obligations under this Addendum; or (ii) an assertion by any governmental regulatory agency (or Lender
believes that there is a substantial risk of such assertion) of a failure to comply with Borrower’s obligations under this Addendum, then (A) Lender and Borrower will meet and resolve any such issue in good faith to the satisfaction of
Borrower, Lender, and any governmental regulatory agency, and (B) upon request of Lender, Borrower will cooperate and assist with any assignment of the financing agreements from Hercules Technology III, L.P. to Hercules Technology Growth
Capital, Inc. (the “Assignment Remedy”). Notwithstanding anything to the contrary in this Agreement, pending the completion of such resolution meeting pursuant to clause (B) above, no default or Event of Default shall have, or be
deemed to have, occurred, provided that if such resolution meeting does not result in a cure or waiver of any such failure to comply, the Assignment Remedy shall be effectuated and, for clarity, no default or Event of Default shall have or be deemed
to have occurred. 

  
 3 

 EXHIBIT A 
 ADVANCE REQUEST 
  

							
	To:	  	 	November 24, 2010	  	  	

 Hercules Technology Growth Capital, Inc. 

Hercules Technology III, L.P. 
 400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Attn: Parag Shah 
 PACIRA PHARMACEUTICALS, INC., a Delaware corporation and Pacira
Pharmaceuticals, Inc., a California corporation (individually, a “Borrower” and collectively, the “Borrowers”) hereby request from Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. (collectively
“Lender”) two Advances in the aggregate amount of $26,250,000 (consisting of one Term Loan A Loan of $11,250,000 and one Term Loan B Loan of $15,000,000 on November 24, 2010 (the “Advance Date”) pursuant to the Loan and
Security Agreement between Borrowers and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Please: 
  

													
		  	(a)	  	Issue a check payable to a Borrower	  	  
	  	
						
		  		  	or                         
   	  		 		  	
					
		  	(b)	  	Wire Funds to a Borrower’s account	  	  
	  	
						
		  		  	Bank:	 	 	 		  	
		  		  	Address:	 	 	 		  	
		  		  		 	 	 		  	
		  		  	ABA Number:	 	 	 		  	
		  		  	Account Number:	 	 	 		  	
		  		  	Account Name:	 	 	 		  	

 Borrowers represent that the conditions precedent to the Advance set forth in the Agreement are
satisfied and shall be satisfied upon the making of such Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the
representations and warranties set forth in the Agreement and in the Warrant are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance in all material respects with all the terms and provisions set forth in each Loan Document on its part to be observed or performed;
and (iv) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrowers understand and acknowledge that
Lender has the right to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance. 

  
 4 

 Borrowers hereby represent that each Borrower’s corporate status and locations have not
changed since the date of the Agreement, except as otherwise permitted under the Agreement. 
 Borrowers agree to notify Lender
promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Borrowing Date and if Lender has received no such notice before the Advance Date then the statements set forth above
shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date. 
 Executed as of
November 24, 2010. 
  

			
	 PACIRA PHARMACEUTICALS, INC., a
 Delaware corporation

		
	By:	 	  

		
	Title:	 	  

		
	Name:	 	  

	
	 PACIRA PHARMACEUTICALS, INC., a
 California corporation

		
	By:	 	  

		
	Title:	 	  

		
	Name:	 	  

  
 5 

 EXHIBIT B 
 SECURED TERM PROMISSORY NOTE 
  

			
	$15,000,000	  	Advance Date: November 24, 2010
		
		  	Maturity Date: May 31, 2014 (subject to extension)

 FOR VALUE RECEIVED, PACIRA PHARMACEUTICALS, INC., a Delaware corporation, and PACIRA PHARMACEUTICALS, INC., a California corporation, (individually, a “Borrower” and collectively, the
“Borrowers”) jointly and severally promise to pay to the order of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301
or such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of Fifteen Million
Dollars ($15,000,000) representing the Term Loan B Loan, or such other principal amount as Lender has advanced to Borrower, together with interest as set forth in the Loan Agreement as defined below. 

This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security
Agreement dated November 24, 2010, by and between Borrowers and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and
security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement.
All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. 

Borrowers waive presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable
law. Borrowers shall make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of
California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other
jurisdiction. 
  

			
	 PACIRA PHARMACEUTICALS, INC., a
 Delaware corporation

		
	By:	 	  

	Title:	 	  

	Name:	 	  

	
	 PACIRA PHARMACEUTICALS, INC., a
 California corporation

		
	By:	 	  

	Name:	 	  

	Title:	 	  

 EXHIBIT B-1 
 SECURED TERM PROMISSORY NOTE 
  

			
	$11,250,000	  	Advance Date: November 24, 2010
		
		  	Maturity Date: May 31, 2014 (subject to extension)

 FOR VALUE RECEIVED, PACIRA PHARMACEUTICALS, INC., a Delaware corporation, and PACIRA PHARMACEUTICALS, INC., a California corporation, (individually, a “Borrower” and collectively, the
“Borrowers”) jointly and severally promise to pay to the order of Hercules Technology III, L.P., a Delaware limited partnership or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or
such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of Eleven Million Two
Hundred Fifty Thousand Dollars ($11,250,000), representing the Term Loan A Loan or such other principal amount as Lender has advanced to Borrower, together with interest as set forth in the Loan Agreement as defined below. 

This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security
Agreement dated November 24, 2010, by and between Borrowers and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and
security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement.
All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. 

Borrowers waive presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable
law. Borrowers shall make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of
California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other
jurisdiction. 
  

			
	 PACIRA PHARMACEUTICALS, INC., a
 Delaware corporation

		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	 PACIRA PHARMACEUTICALS, INC., a
 California corporation

		
	By:	 	  

	Name:	 	  

	Title:	 	  

 EXHIBIT C 
 NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWERS 
 Borrowers represent
and warrant to Lender that each Borrower’s current name and organizational status as of the Closing Date is as follows: 
  

			
	Name:	  	Pacira Pharmaceuticals, Inc., a Delaware corporation:
		
		  	Organization ID
Number:                                    

 Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date, Borrower
did not do business under any other name or organization or form except the following: 
  

	
	
Name:                       
                                         

	 Used during dates
of:                                        
 

	 Type of
Organization:                                       
 

	 State of
organization:                                       
  

	 Organization ID
Number:                                        
        

	 Borrower’s fiscal year ends
on                          

	 Borrower’s federal employer tax identification number is:
                                

 

			
	Name:	  	Pacira Pharmaceuticals, Inc., a California corporation
		
		  	Organization ID
Number:                                    

 Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date, Borrower
did not do business under any other name or organization or form except the following: 
  

	
	
Name:                       
                                         

	 Used during dates
of:                                        
 

	 Type of
Organization:                                       
 

	 State of
organization:                                       
  

	 Organization ID
Number:                                        
        

	 Borrower’s fiscal year ends
on                          

	 Borrower’s federal employer tax identification number is:
                                

Borrowers represent and warrant to Lender that their chief executive office is located at
                                        .

 EXHIBIT D 
 BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 

 EXHIBIT E 
 BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS 

 EXHIBIT F 
 COMPLIANCE CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

Hercules Technology III, L.P. 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 
 Reference is made to that certain Loan and Security Agreement dated November 24, 2010 and all ancillary documents entered into in connection with such Loan and Security Agreement all as may be
amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. (collectively, “Hercules”) as Lender and PACIRA
PHARMACEUTICALS, INC., a Delaware corporation, and PACIRA PHARMACEUTICALS, INC., a California corporation (collectively, the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the
Loan Agreement. 
 The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is
authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance in all material respectsfor the period
ending              of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date
of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of
materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies, in such capacity, that these are prepared in accordance
with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments) and are consistent from one period to the next except as explained below. 

 

					
	REPORTING REQUIREMENT	  	REQUIRED	  	CHECK IF
 ATTACHED

			
	Interim Financial Statements	  	Monthly within 30 days	  	
			
	Interim Financial Statements	  	Quarterly within 45 days	  	
			
	Audited Financial Statements	  	FYE within 150 days (90 if public company)	  	

							
			
		 	     Very Truly Yours,
	 	
			
		 	     PACIRA PHARMACEUTICALS, INC.
	 	
				
		 	     By:
	  	  
	 	
				
		 	     Name:
	  	  
	 	
				
		 	     Title::
	  	  
	 	

 EXHIBIT G 
 FORM OF JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of November 24, 2010, and is entered into by and between                     , a
             corporation (“Subsidiary”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC. and Hercules Technology III, L.P., (collectively, “Lender”). 

RECITALS 

A. Subsidiary’s Affiliate, PACIRA PHARMACEUTICALS, INC. (“Company”) has entered/desires to enter into that certain Loan
and Security Agreement dated November 24, 2010, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
 1. The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement. 

2. By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were
the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other
agreements executed and delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection
therewith, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance
with the Loan Agreement or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have
no right to request an Advance or make any other demand on Lender. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO JOINDER AGREEMENT] 

 

					
	 SUBSIDIARY:
	  		  	
		
	 __________________________________________.
	  	
			
		  	By: ____________________________________________	  	
		  	Name: __________________________________________	  	
		  	Title: ___________________________________________	  	
			
		  	Address:	  	
			
		  	______________________________________________	  	
			
		  	______________________________________________	  	
		  	Telephone: ___________________	  	
		  	Facsimile: ____________________	  	
		
	 HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	  	
			
		  	By: ____________________________________________	  	
		  	Name: __________________________________________	  	
		  	Title: ___________________________________________	  	
			
		  	Address:	  	
		  	 400 Hamilton Ave., Suite 310

Palo Alto, CA 94301
 Facsimile:
650-473-9194
 Telephone: 650-289-3060
	  	

 EXHIBIT H 
 ACH DEBIT AUTHORIZATION AGREEMENT 
 Hercules Technology Growth Capital, Inc. 

Hercules Technology III, L.P. 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 
 Re: Loan and Security Agreement dated November 24, 2010 between Pacira Pharmaceuticals, Inc. (“Borrower”) and Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P.
(collectively, “Company”) (the “Agreement”) 
 In connection with the above referenced Agreement, the Borrower hereby
authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit to such account. 

 

			
	 DEPOSITORY NAME
	 	BRANCH
		
	 CITY
	 	STATE AND ZIP CODE
		
	 TRANSIT/ABA NUMBER
	 	ACCOUNT NUMBER

 This authority will remain in full force
and effect so long as any amounts are due under the Agreement. 
  

	
	 PACIRA PHARMACEUTICAL, INC.

a California corporation

	
	 (Borrower)(Please Print)

	
	 By: ________________________________________

	
	 Date: _______________________________________

	
	 PACIRA PHARMACEUTICAL, INC.

a Delaware corporation

	
	 (Borrower)(Please Print)

	
	 By: ________________________________________

	
	 Date: _______________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]